Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well giving pembrolizumab followed by chemotherapy with
doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin
lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb)" that uses the
body's immune system to help fight and kill cancer cells. Chemotherapy drugs, such as
doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing or by stopping them from
spreading. Giving pembrolizumab followed by chemotherapy may work to treat patients with
classical Hodgkin lymphoma.